Help make the NeuroSens coverage of the ACTRIMS Forum 2026 relevant to you.
Complete the survey below to tell us what topics are of greatest interest to you.
Neurology
PRL detected in optic chiasm
January 30, 2026A newly-published postmortem study has reported that paramagnetic rim lesions (PRL) can occur in the optic chiasm in MS patients (Lockhart et al. Neurology 2026;106:e214515). This is the first report of PRLs detected in the anterior visual pathway. PRLs are most commonly seen in periventricular and deep white-matter lesions in MS patients using 3T or 7T MRI. Read More
BTK inhibitors – a look ahead
January 20, 2026Important new data are expected this year on the efficacy and safety of Bruton’s tyrosine kinase (BTK) inhibitors, a new class of disease-modifying therapies in development for multiple sclerosis. Read More
Adjunctive therapy in focal epilepsy – highlights from AES 2025
December 23, 2025Real-world use of cenobamate
New phase III data
Effect on mortality
Co-administration with cannabidiol
The International League Against Epilepsy (ILAE) published its updated classification of epileptic seizures earlier this year, maintaining four seizure classes (Focal, Generalized, Unknown, Unclassified) and 21 seizure types (Beniczky et al. Epilepsia 2025;66:1804-1823). For example, focal seizures may be classified as focal preserved consciousness (FPC), focal impaired consciousness (FIC) or focal-to-bilateral tonic-clonic seizures (FBTC). Consciousness was defined by awareness (i.e. recall of events) and responsiveness. The basic descriptors are whether seizures have observable manifestations or not.
Read More
High-efficacy DMTs for MS: the year in review
December 1, 2025Click here to complete the interactive survey on DMTs.
Once you submit your responses, you will be able to view all of your colleagues’ responses.
Early use of HE-DMTs
Use in pregnancy
Noteworthy studies in 2025
Switching between anti-CD20 agents
The year 2025 saw an increasing early use of high-efficacy disease-modifying therapies (HE-DMT) in patients with multiple sclerosis, either as the first-choice agent or for the first switch. The rationale for this change in practice patterns derived from the accumulating efficacy and safety data from clinical trials, database analyses and real-world studies on the use of anti-CD20 monoclonal antibodies.
Read More